why choose us

First received: March 22, 2023

Clinical Trial: A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Lymphoma

Study Type: INTERVENTIONAL


Official Title: A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

Brief Summary: The goal of this research study is to evaluate the combination of study drugs, Glofitamab and Polatuzumab, and a standard chemotherapy regimen, R-CHP, as a treatment for high-risk diffuse large B-cell lymphoma.The names of the treatment interventions involved in this study are:Glofitamab (T-cell bispecific antibody)Polatuzumab (antibody-drug conjugate)R-CHP (a chemotherapy regimen comprised of Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, and Prednisone)

Read more